Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis

Background: Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are prone to infections.Aims: Provide a pooled estimate of the cumulative incidence for infections that fulfilled the criteria associated with severe infectious adverse events for grade 3 or higher (includi...

Full description

Bibliographic Details
Main Authors:	Stephanos Vassilopoulos, Fadi Shehadeh, Markos Kalligeros, Quynh-Lam Tran, Fred Schiffman, Eleftherios Mylonakis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Pharmacology
Subjects:	chronic lymphocytic leukemia (CLL) infections targeted therapies ibrutinib idelalisib monoclonal antibodies
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.989830/full

Similar Items

Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2023-03-01)

The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2022-10-01)

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Lorenzo Falchi, et al.
Published: (2016-02-01)

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
by: Otašević Vladimir, et al.
Published: (2019-01-01)

Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study
by: Yazed Saleh Alsowaida, et al.
Published: (2023-02-01)

Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
by: Konstantinos Ouranos, et al.
Published: (2024-01-01)

Risk Factors for Hospital Readmission for <i>Clostridioides difficile</i> Infection: A Statewide Retrospective Cohort Study
by: Gregorio Benitez, et al.
Published: (2022-05-01)

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
by: St-Pierre F, et al.
Published: (2022-07-01)

Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination
by: Markos Kalligeros, et al.
Published: (2021-09-01)

Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study
by: Sophia L. Song, et al.
Published: (2020-09-01)

Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib
by: Baustin M. Welch, et al.
Published: (2023-12-01)

The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
by: Alexandria P. Eiken, et al.
Published: (2024-08-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01)

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
by: Daphne Guinn, et al.
Published: (2017-04-01)

Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective
by: Jacqueline Costello, et al.
Published: (2021-09-01)

Case report: HSV lymphadenitis in immunocompromised patient with CLL
by: Talal Al-Assil, et al.
Published: (2024-12-01)

Possibilities of therapy recurrent b-cell chronic lymphocytic leukemia associated with autoimmune complications: data from literature and personal observation
by: S. R. Goryacheva, et al.
Published: (2018-07-01)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
by: Anthony Mato, et al.
Published: (2023-02-01)

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
by: Ana-Maria Moldovianu, et al.
Published: (2023-02-01)

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
by: Tambaro FP, et al.
Published: (2021-10-01)

A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL
by: Can Chen, et al.
Published: (2023-03-01)

Management of infections for patient treated with ibrutinib in clinical practice
by: Claudia Baratè, et al.
Published: (2024-09-01)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells
by: Amineh Ghaderi, et al.
Published: (2021-08-01)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
by: Arne Trummer, et al.
Published: (2022-01-01)

A case of early ocular manifestation of maculopathy in a 37 yr old male patient of CLL
by: Sufia Ahmad Khan, et al.
Published: (2014-08-01)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
by: Annamaria Mascolo, et al.
Published: (2023-08-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
by: Nuttall E, et al.
Published: (2019-07-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

Editorial: Biology and treatment of high-risk CLL
by: Eugen Tausch, et al.
Published: (2023-02-01)

Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia
by: Kevin Y. Chen, et al.
Published: (2020-03-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis
by: Ramya Muddasani, et al.
Published: (2020-05-01)

İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
by: Caroline Dartigeas, et al.
Published: (2022-09-01)